{"id":762984,"date":"2023-06-12T08:17:13","date_gmt":"2023-06-12T12:17:13","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/keros-therapeutics-announces-update-to-participation-at-the-goldman-sachs-44th-annual-global-healthcare-conference\/"},"modified":"2023-06-12T08:17:13","modified_gmt":"2023-06-12T12:17:13","slug":"keros-therapeutics-announces-update-to-participation-at-the-goldman-sachs-44th-annual-global-healthcare-conference","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/keros-therapeutics-announces-update-to-participation-at-the-goldman-sachs-44th-annual-global-healthcare-conference\/","title":{"rendered":"Keros Therapeutics Announces Update to Participation at the Goldman Sachs 44th Annual Global Healthcare Conference"},"content":{"rendered":"<div class=\"mw_release\">\n<p align=\"left\">LEXINGTON, Mass., June  12, 2023  (GLOBE NEWSWIRE) &#8212; Keros Therapeutics, Inc. (\u201cKeros\u201d) (Nasdaq: KROS), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel treatments for patients suffering from hematological, pulmonary and cardiovascular disorders with high unmet medical need, today announced that it will not be participating in the previously announced fireside chat presentation during the Goldman Sachs 44th Annual Healthcare Conference on Wednesday, June 14, 2023.<\/p>\n<p>\n        <strong>About Keros Therapeutics, Inc.<\/strong><br \/>\n        <br \/>Keros is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel treatments for patients suffering from hematological, pulmonary and cardiovascular disorders with high unmet medical need. Keros is a leader in understanding the role of the transforming growth factor-beta family of proteins, which are master regulators of red blood cell and platelet production as well as of the growth, repair and maintenance of a number of tissues, including blood vessels and heart tissue. Keros\u2019 lead protein therapeutic product candidate, KER-050, is being developed for the treatment of low blood cell counts, or cytopenias, including anemia and thrombocytopenia, in patients with myelodysplastic syndromes and in patients with myelofibrosis. Keros\u2019 lead small molecule product candidate, KER-047, is being developed for the treatment of functional iron deficiency. Keros\u2019 third product candidate, KER-012, is being developed for the treatment of pulmonary arterial hypertension and for the treatment of cardiovascular disorders.<\/p>\n<p>\n        <strong>Investor Contact:<\/strong><br \/>\n        <br \/>Justin Frantz<br \/><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=a3QNp1RIzjcsLJY4Jxcd56Yh7wEWzwq3qHGmUePW12uFV6Rng3AViQMsmtSAQfDE5RObRnZ-sXU3wUSPCwUPBJaxUj9QP5sA2d80JDvfnrM=\" rel=\"nofollow noopener\" target=\"_blank\">jfrantz@kerostx.com<\/a><br \/>617-221-6042<\/p>\n<p \/>\n      <img decoding=\"async\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODg1NTg5NyM1NjQwODM3IzIxMjU5MzM=\" \/><br \/>\n      <br \/>\n      <img decoding=\"async\" src=\"https:\/\/ml.globenewswire.com\/media\/NDhjNzM0YjYtNjdjZS00OTFkLThmZDItY2EyMTk5NDg3MTcxLTExMzc1MDQ=\/tiny\/Keros-Therapeutics-Inc-.png\" \/>\n    <\/div>\n<div class=\"mw_contactinfo\"><\/div>\n","protected":false},"excerpt":{"rendered":"<p>LEXINGTON, Mass., June 12, 2023 (GLOBE NEWSWIRE) &#8212; Keros Therapeutics, Inc. (\u201cKeros\u201d) (Nasdaq: KROS), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel treatments for patients suffering from hematological, pulmonary and cardiovascular disorders with high unmet medical need, today announced that it will not be participating in the previously announced fireside chat presentation during the Goldman Sachs 44th Annual Healthcare Conference on Wednesday, June 14, 2023. About Keros Therapeutics, Inc. Keros is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel treatments for patients suffering from hematological, pulmonary and cardiovascular disorders with high unmet medical need. Keros is a leader in understanding the role of the transforming growth factor-beta family of proteins, &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/keros-therapeutics-announces-update-to-participation-at-the-goldman-sachs-44th-annual-global-healthcare-conference\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;Keros Therapeutics Announces Update to Participation at the Goldman Sachs 44th Annual Global Healthcare Conference&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-762984","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.8 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Keros Therapeutics Announces Update to Participation at the Goldman Sachs 44th Annual Global Healthcare Conference - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/keros-therapeutics-announces-update-to-participation-at-the-goldman-sachs-44th-annual-global-healthcare-conference\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Keros Therapeutics Announces Update to Participation at the Goldman Sachs 44th Annual Global Healthcare Conference - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"LEXINGTON, Mass., June 12, 2023 (GLOBE NEWSWIRE) &#8212; Keros Therapeutics, Inc. (\u201cKeros\u201d) (Nasdaq: KROS), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel treatments for patients suffering from hematological, pulmonary and cardiovascular disorders with high unmet medical need, today announced that it will not be participating in the previously announced fireside chat presentation during the Goldman Sachs 44th Annual Healthcare Conference on Wednesday, June 14, 2023. About Keros Therapeutics, Inc. Keros is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel treatments for patients suffering from hematological, pulmonary and cardiovascular disorders with high unmet medical need. Keros is a leader in understanding the role of the transforming growth factor-beta family of proteins, &hellip; Continue reading &quot;Keros Therapeutics Announces Update to Participation at the Goldman Sachs 44th Annual Global Healthcare Conference&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/keros-therapeutics-announces-update-to-participation-at-the-goldman-sachs-44th-annual-global-healthcare-conference\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2023-06-12T12:17:13+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODg1NTg5NyM1NjQwODM3IzIxMjU5MzM=\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"1 minute\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/keros-therapeutics-announces-update-to-participation-at-the-goldman-sachs-44th-annual-global-healthcare-conference\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/keros-therapeutics-announces-update-to-participation-at-the-goldman-sachs-44th-annual-global-healthcare-conference\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Keros Therapeutics Announces Update to Participation at the Goldman Sachs 44th Annual Global Healthcare Conference\",\"datePublished\":\"2023-06-12T12:17:13+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/keros-therapeutics-announces-update-to-participation-at-the-goldman-sachs-44th-annual-global-healthcare-conference\\\/\"},\"wordCount\":244,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/keros-therapeutics-announces-update-to-participation-at-the-goldman-sachs-44th-annual-global-healthcare-conference\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODg1NTg5NyM1NjQwODM3IzIxMjU5MzM=\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/keros-therapeutics-announces-update-to-participation-at-the-goldman-sachs-44th-annual-global-healthcare-conference\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/keros-therapeutics-announces-update-to-participation-at-the-goldman-sachs-44th-annual-global-healthcare-conference\\\/\",\"name\":\"Keros Therapeutics Announces Update to Participation at the Goldman Sachs 44th Annual Global Healthcare Conference - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/keros-therapeutics-announces-update-to-participation-at-the-goldman-sachs-44th-annual-global-healthcare-conference\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/keros-therapeutics-announces-update-to-participation-at-the-goldman-sachs-44th-annual-global-healthcare-conference\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODg1NTg5NyM1NjQwODM3IzIxMjU5MzM=\",\"datePublished\":\"2023-06-12T12:17:13+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/keros-therapeutics-announces-update-to-participation-at-the-goldman-sachs-44th-annual-global-healthcare-conference\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/keros-therapeutics-announces-update-to-participation-at-the-goldman-sachs-44th-annual-global-healthcare-conference\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/keros-therapeutics-announces-update-to-participation-at-the-goldman-sachs-44th-annual-global-healthcare-conference\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODg1NTg5NyM1NjQwODM3IzIxMjU5MzM=\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODg1NTg5NyM1NjQwODM3IzIxMjU5MzM=\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/keros-therapeutics-announces-update-to-participation-at-the-goldman-sachs-44th-annual-global-healthcare-conference\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Keros Therapeutics Announces Update to Participation at the Goldman Sachs 44th Annual Global Healthcare Conference\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Keros Therapeutics Announces Update to Participation at the Goldman Sachs 44th Annual Global Healthcare Conference - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/keros-therapeutics-announces-update-to-participation-at-the-goldman-sachs-44th-annual-global-healthcare-conference\/","og_locale":"en_US","og_type":"article","og_title":"Keros Therapeutics Announces Update to Participation at the Goldman Sachs 44th Annual Global Healthcare Conference - Market Newsdesk","og_description":"LEXINGTON, Mass., June 12, 2023 (GLOBE NEWSWIRE) &#8212; Keros Therapeutics, Inc. (\u201cKeros\u201d) (Nasdaq: KROS), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel treatments for patients suffering from hematological, pulmonary and cardiovascular disorders with high unmet medical need, today announced that it will not be participating in the previously announced fireside chat presentation during the Goldman Sachs 44th Annual Healthcare Conference on Wednesday, June 14, 2023. About Keros Therapeutics, Inc. Keros is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel treatments for patients suffering from hematological, pulmonary and cardiovascular disorders with high unmet medical need. Keros is a leader in understanding the role of the transforming growth factor-beta family of proteins, &hellip; Continue reading \"Keros Therapeutics Announces Update to Participation at the Goldman Sachs 44th Annual Global Healthcare Conference\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/keros-therapeutics-announces-update-to-participation-at-the-goldman-sachs-44th-annual-global-healthcare-conference\/","og_site_name":"Market Newsdesk","article_published_time":"2023-06-12T12:17:13+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODg1NTg5NyM1NjQwODM3IzIxMjU5MzM=","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/keros-therapeutics-announces-update-to-participation-at-the-goldman-sachs-44th-annual-global-healthcare-conference\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/keros-therapeutics-announces-update-to-participation-at-the-goldman-sachs-44th-annual-global-healthcare-conference\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Keros Therapeutics Announces Update to Participation at the Goldman Sachs 44th Annual Global Healthcare Conference","datePublished":"2023-06-12T12:17:13+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/keros-therapeutics-announces-update-to-participation-at-the-goldman-sachs-44th-annual-global-healthcare-conference\/"},"wordCount":244,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/keros-therapeutics-announces-update-to-participation-at-the-goldman-sachs-44th-annual-global-healthcare-conference\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODg1NTg5NyM1NjQwODM3IzIxMjU5MzM=","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/keros-therapeutics-announces-update-to-participation-at-the-goldman-sachs-44th-annual-global-healthcare-conference\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/keros-therapeutics-announces-update-to-participation-at-the-goldman-sachs-44th-annual-global-healthcare-conference\/","name":"Keros Therapeutics Announces Update to Participation at the Goldman Sachs 44th Annual Global Healthcare Conference - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/keros-therapeutics-announces-update-to-participation-at-the-goldman-sachs-44th-annual-global-healthcare-conference\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/keros-therapeutics-announces-update-to-participation-at-the-goldman-sachs-44th-annual-global-healthcare-conference\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODg1NTg5NyM1NjQwODM3IzIxMjU5MzM=","datePublished":"2023-06-12T12:17:13+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/keros-therapeutics-announces-update-to-participation-at-the-goldman-sachs-44th-annual-global-healthcare-conference\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/keros-therapeutics-announces-update-to-participation-at-the-goldman-sachs-44th-annual-global-healthcare-conference\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/keros-therapeutics-announces-update-to-participation-at-the-goldman-sachs-44th-annual-global-healthcare-conference\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODg1NTg5NyM1NjQwODM3IzIxMjU5MzM=","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODg1NTg5NyM1NjQwODM3IzIxMjU5MzM="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/keros-therapeutics-announces-update-to-participation-at-the-goldman-sachs-44th-annual-global-healthcare-conference\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Keros Therapeutics Announces Update to Participation at the Goldman Sachs 44th Annual Global Healthcare Conference"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/762984","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=762984"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/762984\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=762984"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=762984"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=762984"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}